Transgene (LTS:0OCQ) Other Long-Term Liabilities: €0.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCQ Transgene SA LTS:0OCQ
41 GF Score
Price €0.86
GF Value €0.50
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Other Long-Term Liabilities?

Transgene LTS:0OCQ +0.12% 41 Other Long-Term Liabilities is €0.55 Mil as of Dec. 2025. GuruFocus rates LTS:0OCQ with a GF Score™ of 41/100 and a GF Value™ of €0.50 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Transgene's other long-term liabilities for the quarter that ended in Dec. 2025 was €0.55 Mil.

Transgene's quarterly other long-term liabilities increased from Dec. 2024 (€-0.00 Mil) to Jun. 2025 (€0.00 Mil) and increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.55 Mil).

Transgene's annual other long-term liabilities declined from Dec. 2023 (€16.20 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€0.55 Mil).

Transgene Other Long-Term Liabilities Related Terms

Transgene Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Transgene's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Other Long-Term Liabilities Chart

Transgene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.63 11.27 16.20 -0.00 0.55

Transgene Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.20 36.06 -0.00 0.00 0.55
LTS:0OCQ
41GF Score
Transgene SA LTS:0OCQ
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0.55 Mil mean?
Transgene (LTS:0OCQ) has a Other Long-Term Liabilities of €0.55 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Transgene and its competitors.
Is Transgene's Other Long-Term Liabilities too high?
Transgene's current Other Long-Term Liabilities is €0.55 Mil. Overall, Transgene has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's Other Long-Term Liabilities compare to VRTX and REGN?
Transgene's Other Long-Term Liabilities of €0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Transgene and its competitors. Transgene's current Other Long-Term Liabilities is €0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (LTS:0OCQ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.50, compared to a current price of €0.86 — trading 71% above its estimated fair value. The current Other Long-Term Liabilities is €0.55 Mil. Transgene's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Transgene (LTS:0OCQ), the current Other Long-Term Liabilities is €0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene (LTS:0OCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.86 is trading 71% above its estimated GF Value™ of €0.50. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for LTS:0OCQ:

  • Other Long-Term Liabilities: €0.55 Mil
  • GF Value™: €0.50 vs. price of €0.86 (71% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
41GF Score

Get the complete analysis for LTS:0OCQ

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€0.50
GF Value